Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide for PAM50 HER2-enriched endocrine-resistant HR-positive/HER2-negative metastatic breast cancer
2019-002806-28Phase 2Terminated
- Sponsor
- SOLTI
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of enzalutamide in breast cancer (2 cohorts), sponsored by SOLTI. Primary endpoint: Relative change in PAM50 11-gene proliferation signature after 2 weeks. Started Sep 2019; status: terminated.
02
Drugs
enzalutamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-002806-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002806-28.